Exocrine Pancreatic Insufficiency

Definition And Pathophysiology

Characterized by insufficient secretion of pancreatic enzymes (acinar function) or sodium bicarbonate (ductal function).
Results in severe maldigestion and malabsorption of nutrients, predominantly fat.
Massive functional reserve exists; clinically significant malabsorption requires destruction of >90-95% of exocrine pancreatic mass.

Cystic Fibrosis (CF): CFTR gene mutations impair apical chloride and bicarbonate transport. Secretions become acidic, dehydrated, and protein-rich, causing intraluminal plugging. Results in acinar degeneration, fibrosis, and progressive fatty replacement.
Shwachman-Diamond Syndrome (SDS): Characterized by extensive fatty infiltration of the pancreas without ductal involvement.
Secondary Insufficiency: Proximal small bowel mucosal inflammation (celiac disease, Crohn disease) impairs release of secretin and cholecystokinin (CCK), removing trophic stimulation for pancreatic secretion.

Category	Specific Disorders
Primary/Genetic Defects	Cystic fibrosis (most common). Shwachman-Diamond syndrome. Johanson-Blizzard syndrome. Pearson marrow-pancreas syndrome. Isolated enzyme deficiencies (lipase, enterokinase, trypsinogen). Hereditary pancreatitis (PRSS1, SPINK1 mutations).
Secondary/Acquired Defects	Chronic pancreatitis. Severe protein-calorie malnutrition. Celiac disease.Inflammatory bowel disease.Surgical resection (pancreatectomy, gastrectomy, extensive bowel resection).

System	Manifestations
Gastrointestinal	Steatorrhea (bulky, foul-smelling, oily stools). Chronic diarrhea, flatulence, abdominal bloating.
Nutritional	Failure to thrive, poor weight gain, short stature.Fat-soluble vitamin deficiencies (A, D, E, K).Trace mineral deficiencies (zinc, iron, magnesium).

Fecal Elastase-1: Monoclonal ELISA assay highly specific to human enzyme. Test of choice due to broad availability and ease. Value <200 ug/g suggests insufficiency; <100 ug/g confirms severe insufficiency. Unaffected by exogenous porcine enzyme therapy. May yield false-low results in watery diarrhea.
72-Hour Fecal Fat Excretion: Gold standard for quantifying fat malabsorption. Coefficient of fat absorption <93% (in children >6 months) indicates abnormality. Cumbersome, low patient compliance.
Serum Immunoreactive Trypsinogen (IRT): Elevated in newborns with CF; subnormal levels in older children indicate pancreatic acinar destruction.

Involves endoscopic or tube collection of duodenal fluid following intravenous secretin or CCK stimulation.
Measures pH, fluid volume, bicarbonate, and specific enzyme concentrations.
Highly sensitive but invasive; requires sedation/anesthesia.

Ultrasonography/CT/MRI: Demonstrates atrophied gland, calcifications, or fatty replacement typical of CF or SDS.

Mainstay intervention for clinical insufficiency.
Utilizes enteric-coated, porcine-derived microspheres.
Dosage Guidelines:
- Age <4 years: 1000 lipase units/kg/meal.
- Age >4 years: 500 lipase units/kg/meal.
- Snacks require half the standard meal dose.
Safety Threshold: Strictly maintain dose <10,000 lipase units/kg/day to prevent fibrosing colonopathy.
Administration: Open capsules, sprinkle contents on acidic, soft foods (applesauce). Avoid crushing microspheres or mixing with alkaline foods (milk, dairy) to preserve enteric coating.

Acid Suppression: Initiate proton pump inhibitors (PPI) or H2-receptor antagonists.
Neutralizes gastric acid, preventing premature degradation of supplemental enzymes and improving PERT efficacy.